FindTrial
Sign In

Impact of renin-angiotensin system inhibitors on peritoneal inflammation and fibrosis in peritoneal dialysis

Impact of renin-angiotensin system inhibitors on peritoneal inflammation and fibrosis in peritoneal dialysis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032600
Enrollment
Unknown
Registered
2020-05-03
Start date
2020-05-06
Completion date
Unknown
Last updated
2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritoneal inflammation and fibrosis

Interventions

Exposure group:take ACEI / ARB drugs
control group:no ACEI/ARB drugs

Sponsors

Hong Kong University, Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Peritoneal dialysis patients aged 20-80

Exclusion criteria

Exclusion criteria: Severe systemic inflammatory disease, peritonitis, tumor or pregnancy.

Design outcomes

Primary

MeasureTime frame
KT/V;Peritoneal transport function;CA125;—

Secondary

MeasureTime frame
IL-6;Fibronectin;HA;TGF-beta;MMP-2;TNF-alpha;VEGF;PAI-1;—

Countries

China

Contacts

Public ContactChenzhu Zhang

Hong Kong University, Shenzhen Hospital

zhangcz@hku-szh.org+86 13632997934

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026